- Home
- PCSA vs STSS Comparison
PCSA vs STSS Comparison
Compare PCSA & STSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCSA
- STSS
- Stock Information
- Founded
- PCSA 2011
- STSS 2017
- Country
- PCSA United States
- STSS United States
- Employees
- PCSA N/A
- STSS N/A
- Industry
- PCSA Biotechnology: Pharmaceutical Preparations
- STSS Medical/Dental Instruments
- Sector
- PCSA Health Care
- STSS Health Care
- Exchange
- PCSA Nasdaq
- STSS Nasdaq
- Market Cap
- PCSA 4.3M
- STSS 5.1M
- IPO Year
- PCSA N/A
- STSS 2022
- Fundamental
- Price
- PCSA $0.86
- STSS $3.47
- Analyst Decision
- PCSA Buy
- STSS
- Analyst Count
- PCSA 3
- STSS 0
- Target Price
- PCSA $5.00
- STSS N/A
- AVG Volume (30 Days)
- PCSA 26.8K
- STSS 63.4K
- Earning Date
- PCSA 10-30-2024
- STSS 11-14-2024
- Dividend Yield
- PCSA N/A
- STSS N/A
- EPS Growth
- PCSA N/A
- STSS N/A
- EPS
- PCSA N/A
- STSS N/A
- Revenue
- PCSA N/A
- STSS N/A
- Revenue This Year
- PCSA N/A
- STSS N/A
- Revenue Next Year
- PCSA N/A
- STSS N/A
- P/E Ratio
- PCSA N/A
- STSS N/A
- Revenue Growth
- PCSA N/A
- STSS N/A
- 52 Week Low
- PCSA $0.85
- STSS $2.34
- 52 Week High
- PCSA $17.40
- STSS $18.15
- Technical
- Relative Strength Index (RSI)
- PCSA 21.42
- STSS 60.04
- Support Level
- PCSA $0.85
- STSS $2.54
- Resistance Level
- PCSA $1.06
- STSS $2.99
- Average True Range (ATR)
- PCSA 0.08
- STSS 0.33
- MACD
- PCSA -0.02
- STSS 0.12
- Stochastic Oscillator
- PCSA 2.89
- STSS 81.58
About PCSA Processa Pharmaceuticals Inc.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its "regulatory science" approach in the development of Next Generation Chemotherapy ("NGC") oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small molecule oncology drugs. The NGC products are new chemical entities, but the company work by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are - NGC-Capecitabine (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).
About STSS Sharps Technology Inc.
Sharps Technology Inc is a medical device company. It offers syringes and other safety products. Sharps provensa, Securgard, and Sologard are ultra-low waste smart safety syringes are designed to eliminate potentially infectious and accidental needlestick injuries.